

**Supplement 2. Eligibility criteria for study inclusion**

**INCLUSION/EXCLUSION FORM**

---

<b>Reviewer ID:</b>	<b>Date:</b> /    /2015	<b>Record ID:</b>
---------------------	-------------------------	-------------------

---

---

<b>Criteria</b>	<b>Yes</b>	<b>No</b>	<b>UC</b>
-----------------	------------	-----------	-----------

---

**1. PUBLICATION TYPE**

a. Primary research (RCTs, cohort studies, case control studies, case reports, and case series)

Exclude:

- Systematic reviews, letters to editor, commentaries

---

**2. Population**

a. Children ≤6 years of age, where age subgroups data is available:

Unclear:

- If aggregate/subgroup data include but are not limited to age ≤6 years

Exclude:

- If data is reported in aggregate with older ages

---

**3. CONDITION**

a. Children with acute respiratory disease (any of the following):

- Bronchiolitis
- Croup
- Acute wheeze/asthma
- Acute uncomplicated pneumonia (no abscess, effusion, etc)
- Pharyngitis/tonsillitis
- Peritonsillar abscess
- Acute sinusitis
- Respiratory syncytial virus/ rhinovirus/other viruses
- Respiratory distress due to foreign bodies
- PFAPA syndrome

Exclude:

- patients in NICU, PICU
- respiratory distress syndrome (newborn)
- allergic rhinitis
- animal studies

---

**4. Intervention**

---

- 
- a. All inhaled\* and systemic (IV, IM, oral) corticosteroids used for  $\leq 14$  days per course, including (but not limited to):
- Beclomethasone
  - Budesonide
  - Ciclesonide
  - Dexamethasone
  - Fluticasone propionate
  - Mometasone furoate
  - Prednisolone
  - Prednisone
  - Triamcinolone acetonide
  - combination therapies (e.g. ICS + short-acting beta-agonists)

Exclude

- topical (non-systemic) corticosteroid therapy

\* inhaled (moderate- to high-dose) corticosteroids, following GINA guidelines for low doses for children 5 years and younger (see Box 6-6 below).

---

### 5. Comparator group (where relevant)

- a. Any comparison, including non-pharmacologic interventions which may act similarly to a placebo

---

### 6. OUTCOME

Adverse drug reaction, side effect, adverse effects/events, adverse reactions

---

### 7. Setting

Focus is on outpatient settings (e.g. ambulatory, ED), and hospitalised patients

Exclude

- patients in NICU, PICU

---

Comments:

GINA Global Strategy for Asthma Management and Prevention:

[http://www.ginasthma.org/local/uploads/files/GINA\\_Report\\_2014\\_Jun11.pdf](http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf)

#### Box 6-6. Low daily doses of inhaled corticosteroids for children 5 years and younger

Drug	Low daily dose (mcg)
Beclomethasone dipropionate (HFA)	100
Budesonide pMDI + spacer	200

Budesonide nebulized	500
Fluticasone proprionate (HFA)	100
Ciclesonide	160
Mometasone furoate	Not studied below age 4 years
Triamcinolone acetonide	Not studied in this age group